Shan Hu, Zhen Guo, and Chenze Li review coronary artery disease advancements

Recent advancements in coronary artery disease drug development are reshaping patient care through novel lipid-lowering agents, targeted anti-inflammatory therapies, and precision medicine frameworks. According to a state-of-the-art review published in Cardiovascular Innovations and Applications (CVIA) in 2026 by Shan Hu, Zhen Guo, and Chenze Li, these innovations expand therapeutic options for high-risk populations by integrating … Read more

Spleen Imaging Features Predict Coronary Artery Disease Risk

Hidden features within the spleen detected on abdominal imaging scans can signal a person’s risk of developing coronary artery disease, according to a new study published in Science Translational Medicine. Led by investigators from Mass General Brigham, the research leverages artificial intelligence and genomic analyses to uncover how blood-forming and immune functions in the spleen … Read more

TAVI vs. PCI: New Trial Shows TAVI-First Strategy Noninferior

A TAVI-first strategy for patients with severe aortic stenosis and concomitant coronary artery disease is noninferior to a PCI-first approach at one year, according to clinical trial results presented at the ESC Congress 2026 and published simultaneously in the New England Journal of Medicine. Researchers evaluated 986 patients across 48 centers to compare the competing … Read more

How Immune Cells Drive Hidden Inflammation After Heart Attacks

According to researchers at Linköping University, patients with stable coronary artery disease suffer from silent, low-grade inflammation driven by dysregulated immune cells known as neutrophils, which fail to die off as expected even when optimally treated. Over 20,000 people in Sweden experience a heart attack every year, and while modern treatments like balloon angioplasty and … Read more